BR112019003007A2 - terapia tópica regional neuro-afetiva com cariopileno - Google Patents
terapia tópica regional neuro-afetiva com cariopilenoInfo
- Publication number
- BR112019003007A2 BR112019003007A2 BR112019003007-7A BR112019003007A BR112019003007A2 BR 112019003007 A2 BR112019003007 A2 BR 112019003007A2 BR 112019003007 A BR112019003007 A BR 112019003007A BR 112019003007 A2 BR112019003007 A2 BR 112019003007A2
- Authority
- BR
- Brazil
- Prior art keywords
- cariopylene
- neuropathic
- topical therapy
- therapy
- topical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
é descrito um método de tratamento de um estado ou condição de doença em humanos através da terapia de estimulação tópica aferente do tronco cerebral através da administração de cariofileno na parte de trás do pescoço de um paciente humano para fornecer terapia regional neuro-afetiva. em certas modalidades, os fármacos são incorporados em um transportador tópico farmaceuticamente aceitável, por exemplo, um creme, gel, loção ou espuma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/238,118 US20180049994A1 (en) | 2016-08-16 | 2016-08-16 | Topical regional neuro-affective therapy with caryophyllene |
US15/238,118 | 2016-08-16 | ||
PCT/US2017/047122 WO2018035212A1 (en) | 2016-08-16 | 2017-08-16 | Topical regional neuro-affective therapy with caryophyllene |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019003007A2 true BR112019003007A2 (pt) | 2019-05-14 |
Family
ID=61191025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019003007-7A BR112019003007A2 (pt) | 2016-08-16 | 2017-08-16 | terapia tópica regional neuro-afetiva com cariopileno |
Country Status (8)
Country | Link |
---|---|
US (2) | US20180049994A1 (pt) |
EP (1) | EP3500235A4 (pt) |
JP (1) | JP2019528277A (pt) |
AU (1) | AU2017313063A1 (pt) |
BR (1) | BR112019003007A2 (pt) |
CA (1) | CA3034250A1 (pt) |
MX (1) | MX2019001818A (pt) |
WO (1) | WO2018035212A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10543176B2 (en) * | 2017-06-20 | 2020-01-28 | Jessica Kado | Topical formulation for binding to dermatological cannabinoid receptors |
IT201800004027A1 (it) * | 2018-03-28 | 2019-09-28 | Jointherapeutics S R L | Composizione per il trattamento di patologie infiammatorie |
US20210322312A1 (en) * | 2018-08-17 | 2021-10-21 | Kirsten K. Shepard | Cannabidiol composition and methods thereof |
CN113557012A (zh) * | 2018-11-08 | 2021-10-26 | Gbs全球生物制药公司 | 包封萜类化合物和/或大麻素的治疗性纳米颗粒 |
US20220378718A1 (en) | 2019-05-28 | 2022-12-01 | Tech Swerve Llc | Penetrating topical pain relief compositions and methods of use |
CA3141993A1 (en) | 2019-05-28 | 2020-12-03 | Tech Swerve Llc | Penetrating topical pain relief compositions and methods of use |
US10588871B1 (en) | 2019-06-28 | 2020-03-17 | Nexzol Pharma, Inc. | Transdermal formulation for the treatment of pain and/or inflammation |
WO2021046459A1 (en) | 2019-09-04 | 2021-03-11 | Amare Global | Nutritional supplements and methods of nutritional supplementation affecting heart/brain axis |
WO2021046450A1 (en) * | 2019-09-04 | 2021-03-11 | Amare Global | Nutritional supplements and methods of supplementation affecting the endocannabinoid system |
AU2020343016A1 (en) | 2019-09-04 | 2022-04-14 | Amare Global | Nutritional supplements and methods of nutritional supplementation affecting mood and focus in children |
US20220401382A1 (en) * | 2019-11-14 | 2022-12-22 | Natural Extraction Systems, LLC | Methods of preventing and treating health conditions using cannabinoid anions |
US20230218693A1 (en) * | 2020-06-12 | 2023-07-13 | Credo Science, Llc | Hemp sprout products and methods for producing same |
CN112107563B (zh) * | 2020-10-19 | 2021-07-23 | 中国科学院动物研究所 | 一种影响人和动物对冷感知的化合物及其应用 |
CN113304272B (zh) * | 2021-04-19 | 2023-08-25 | 南京中医药大学 | β-石竹烯透皮吸收促进剂及其在外用制剂、化妆品中的应用 |
WO2023152624A1 (en) * | 2022-02-08 | 2023-08-17 | Buzzelet Development And Technologies Ltd. | Methods for the treatment of tinnitus |
IT202200004340A1 (it) * | 2022-03-08 | 2023-09-08 | Pharmaceutica San Marco S R L | Composizione o associazione di composti preferibilmente per l’uso nel trattamento di malattie nervose in particolare neurodegenerative, metodo per la preparazione di tale composizione o associazione di composti e suoi impieghi |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4262003A (en) | 1975-12-08 | 1981-04-14 | Alza Corporation | Method and therapeutic system for administering scopolamine transdermally |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4767619A (en) | 1981-09-14 | 1988-08-30 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Burn wound dressing material |
GR79215B (pt) | 1982-06-07 | 1984-10-22 | Glaxo Group Ltd | |
US4511563A (en) | 1983-07-15 | 1985-04-16 | Basf Wyandotte Corporation | Clear analgesic gels with reduced tackiness |
US5364628A (en) | 1985-05-31 | 1994-11-15 | Sandoz Ltd. | Pharmaceutical compositions |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
GB8419575D0 (en) | 1984-08-01 | 1984-09-05 | Glaxo Group Ltd | Chemical compounds |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US5016652A (en) | 1985-04-25 | 1991-05-21 | The Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
DE3710216A1 (de) | 1987-03-27 | 1988-10-06 | Rentschler Arzneimittel | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen |
US4997841A (en) | 1987-08-13 | 1991-03-05 | Glaxo Group Limited | Indole derivatives |
US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4883660A (en) | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
US5053227A (en) | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
YU48855B (sh) | 1990-06-07 | 2002-06-19 | The Wellcome Foundation Limited | Heterociklična jedinjenja i njihovi derivati koji su modifikatori dejstva 5-hidroksi-triptamina i postupak njihovog dobijanja |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
WO1992006973A1 (en) | 1990-10-15 | 1992-04-30 | Pfizer Inc. | Indole derivatives |
GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
GB9104890D0 (en) | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
GB9125699D0 (en) | 1991-12-03 | 1992-01-29 | Glaxo Group Ltd | Device |
DE4314976C1 (de) | 1993-05-06 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5807571A (en) | 1993-05-06 | 1998-09-15 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic systems for administering indole serotonin agonists |
AU7517794A (en) | 1993-08-16 | 1995-03-14 | Cygnus Therapeutic Systems | Transdermal delivery system using a combination of permeation enhancers |
KR960015375B1 (ko) | 1994-06-08 | 1996-11-11 | 현대전자산업 주식회사 | 강유전체 박막 제조장치 및 그를 사용한 강유전체 박막 제조방법 |
US5698571A (en) | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
US5562917A (en) | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
NZ322588A (en) | 1995-11-13 | 1999-01-28 | Pitmy Int Nv | An administration medium containing nitrous oxide for use in conjunction with analgesics, anti-inflammatories and anti-pyretics to enhance their action |
US5708187A (en) | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
US5837289A (en) | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
US5872145A (en) | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US6197331B1 (en) | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
US6103266A (en) | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
DE69922688T2 (de) | 1998-11-02 | 2005-12-01 | Merck & Co. Inc. | Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6203796B1 (en) * | 1999-07-08 | 2001-03-20 | Andreas D. Papaprodromou | Oregano-based therapeutic composition |
SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
US20020165207A1 (en) | 2001-05-02 | 2002-11-07 | Richard Rosenbloom | Compositions and methods for the treatment of diabetic neuropathy |
US6555573B2 (en) | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
US6916823B2 (en) | 2001-01-16 | 2005-07-12 | Purdue Research Foundation | Method of treatment of dopamine-related dysfunction |
US20080038363A1 (en) | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
DK1435945T3 (da) | 2001-06-05 | 2008-12-01 | Ronald Aung-Din | Topisk migræne terapi |
WO2003024456A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating and preventing migraines |
US6455557B1 (en) | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
US20030167556A1 (en) | 2002-03-05 | 2003-09-11 | Consumers Choice Systems, Inc. | Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
WO2004112723A2 (en) | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
WO2005000086A2 (en) | 2003-06-30 | 2005-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS |
US8263574B2 (en) | 2004-09-29 | 2012-09-11 | James L. Schaller, P.A. | Topical formulations for the treatment of depression with S adenosyl methionine |
BR122016029094B1 (pt) * | 2004-10-01 | 2021-10-13 | Aché Laboratórios Farmacêuticos S.A | Composição farmacêutica anti-inflamatória |
CA2650853A1 (en) | 2006-05-02 | 2007-11-15 | Chris Rundfeldt | Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms |
US20090247619A1 (en) | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
AU2009269129B2 (en) | 2008-06-30 | 2015-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
WO2010036937A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
AU2009345154A1 (en) | 2009-04-29 | 2011-12-22 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
ES2635084T3 (es) * | 2009-08-31 | 2017-10-02 | Zynerba Pharmaceuticals, Inc. | Uso de profármacos de cannabidiol en administración tópica y transdérmica con microagujas |
EP2444081B1 (en) | 2010-10-19 | 2015-04-08 | Parenteral, A.S. | A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol |
IT1403677B1 (it) * | 2011-02-02 | 2013-10-31 | Sofedus Srl | Nuova associazione per il trattamento del dolore |
US20140030289A1 (en) * | 2011-02-06 | 2014-01-30 | Rivka Ofir | Compositions comprising beta-caryophyllene and methods of utilizing the same |
WO2013009928A1 (en) | 2011-07-11 | 2013-01-17 | Organic Medical Research | Cannabinoid formulations |
WO2013140342A1 (en) | 2012-03-19 | 2013-09-26 | Ariel-University Research And Development Company, Ltd. | Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists |
US9345659B2 (en) * | 2012-12-11 | 2016-05-24 | Avon Products, Inc. | Use of melicope extracts to improve conditions caused by excess lipids |
WO2015000064A1 (en) * | 2013-07-05 | 2015-01-08 | Evans Donna | Composition for treating pain and/or inflammation comprising eugenol and beta-caryophyllene |
AU2014347807A1 (en) * | 2013-10-31 | 2016-05-26 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
US9044390B1 (en) * | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
CN106794168A (zh) | 2014-07-21 | 2017-05-31 | 格利亚有限责任公司 | 用大麻素治疗放疗和化疗相关的认知或情感损伤的方法 |
EP3209312A1 (en) | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
-
2016
- 2016-08-16 US US15/238,118 patent/US20180049994A1/en not_active Abandoned
-
2017
- 2017-08-16 CA CA3034250A patent/CA3034250A1/en not_active Abandoned
- 2017-08-16 JP JP2019508933A patent/JP2019528277A/ja active Pending
- 2017-08-16 EP EP17842049.3A patent/EP3500235A4/en not_active Withdrawn
- 2017-08-16 BR BR112019003007-7A patent/BR112019003007A2/pt not_active Application Discontinuation
- 2017-08-16 AU AU2017313063A patent/AU2017313063A1/en not_active Abandoned
- 2017-08-16 MX MX2019001818A patent/MX2019001818A/es unknown
- 2017-08-16 WO PCT/US2017/047122 patent/WO2018035212A1/en unknown
-
2019
- 2019-05-22 US US16/419,766 patent/US10828266B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10828266B2 (en) | 2020-11-10 |
AU2017313063A1 (en) | 2019-03-07 |
EP3500235A1 (en) | 2019-06-26 |
WO2018035212A1 (en) | 2018-02-22 |
CA3034250A1 (en) | 2018-02-22 |
JP2019528277A (ja) | 2019-10-10 |
EP3500235A4 (en) | 2020-04-29 |
MX2019001818A (es) | 2019-08-22 |
US20180049994A1 (en) | 2018-02-22 |
US20190274969A1 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019003007A2 (pt) | terapia tópica regional neuro-afetiva com cariopileno | |
MX2017011280A (es) | Terapia neuro-afectiva regional topica con cannabinoides. | |
BR112016024472A2 (pt) | composto, medicamento, métodos para modulação alostérica positiva e para profilaxia ou tratamento de doenças, e, uso de um composto | |
BR112014009851A2 (pt) | moduladores de receptor de nmda e usos dos mesmos | |
BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
BR112016014830A2 (pt) | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp | |
MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
PH12016500715A1 (en) | Di-isopropyl-phosphinoyl-alkane (dapa) compounds as topical agents for the treatment of sensory discomfort | |
MX337830B (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas. | |
MX2017013852A (es) | Produccion escalable de vesiculas extracelulares estandarizadas, preparaciones de vesiculas extracelular y usos de estos. | |
MX2021002321A (es) | Nuevos metodos. | |
BR112017023170A2 (pt) | dispositivo de banho medicinal e seu uso | |
NZ759173A (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
BR112014018450A8 (pt) | Fenilimidazopirazoles substituídos e sua utilização | |
MX360409B (es) | Terapia de combinacion de dosis fija para la enfermedad de parkinson. | |
WO2018060528A3 (en) | Therapeutic protein | |
MX2015016750A (es) | Composicion inmunogenica para uso en terapia. | |
BR112018001809A2 (pt) | composto de hidroxitriazina e uso médico do mesmo | |
Veraldi et al. | Efficacy and tolerability of topical 0.2% Myrtacine® and 4% vitamin PP for prevention and treatment of retinoid dermatitis in patients with mild to moderate acne | |
MY196026A (en) | Stem Cell Conditioned Media for Clinical and Cosmetic Applications | |
CN104721035A (zh) | 一种穴位磁性按摩发箍及进行头部磁性按摩的方法 | |
BR112018074543A2 (pt) | composição de despigmentação, uso da composição de despigmentação, método para prevenir e/ou reduzir a pigmentação e método para prevenir e/ou reduzir os distúrbios da pigmentação da pele | |
EP2712613A1 (en) | Vitamin K1 and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |